Michael Krachon Net Worth

The estimated Net Worth of Michael Krachon is at least $359 Thousand dollars as of 22 October 2020. Mr. Krachon owns over 28,844 units of Perspective Therapeutics Inc stock worth over $32,196 and over the last 7 years he sold ISR stock worth over $0. In addition, he makes $326,833 as Executive Vice President of Sales and Marketing at Perspective Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Krachon ISR stock SEC Form 4 insiders trading

Michael has made over 3 trades of the Perspective Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 28,844 units of ISR stock worth $14,999 on 22 October 2020.

The largest trade he's ever made was buying 55,000 units of Perspective Therapeutics Inc stock on 20 November 2017 worth over $27,500. On average, Michael trades about 19,121 units every 152 days since 2017. As of 22 October 2020 he still owns at least 83,844 units of Perspective Therapeutics Inc stock.

You can see the complete history of Mr. Krachon stock trades at the bottom of the page.

Michael Krachon biography

Michael Krachon serves as Executive Vice President of Sales and Marketing of the Company., since March 2016. Mr. Krachon brings more than 20 years' experience of progressive growth in sales and marketing in the medical industry to the Company. He joined Isoray in March 2016 as Vice President, Sales and Marketing. Prior to joining Isoray, Mr. Krachon was employed by C.R. Bard Inc. since 2001, and was a key member of the Bard Urological and Medical Division which developed brachytherapy devices and delivery systems for the U.S. and international markets. He was the leader of the brachytherapy commercial team, which grew to be the global brachytherapy market leader. Mr. Krachon assisted in the business unit's strategic planning, development of the international business segment and creating and delivering the international product launches which resulted in market leadership across Europe, Japan and Africa. His responsibilities included: the development of strategic brachytherapy sales and marketing programs; the implementation of industry leading national and international training programs; and supporting the product development process. Finally, Mr. Krachon has been instrumental in successfully supporting the industry through congressional lobbying efforts to establish and maintain reimbursement codes for brachytherapy. He served as Chairman of the Coalition for Advancement of Brachytherapy from 2009 to 2016 and has been recognized as a national speaker for brachytherapy by the industry. Mr. Krachon received a B.S.E. in biomedical engineering from Duke University and his M.B.A. from the Goizueta Business School at Emory University.

What is the salary of Michael Krachon?

As the Executive Vice President of Sales and Marketing of Perspective Therapeutics Inc, the total compensation of Michael Krachon at Perspective Therapeutics Inc is $326,833. There are 2 executives at Perspective Therapeutics Inc getting paid more, with Lori Woods having the highest compensation of $416,524.

How old is Michael Krachon?

Michael Krachon is 48, he's been the Executive Vice President of Sales and Marketing of Perspective Therapeutics Inc since 2020. There are 12 older and 4 younger executives at Perspective Therapeutics Inc. The oldest executive at Perspective Therapeutics Inc is Philip Vitale, 73, who is the Independent Director.

What's Michael Krachon's mailing address?

Michael's mailing address filed with the SEC is 350 HILLS STREET, SUITE 106, RICHLAND, WA, 99354.

Insiders trading at Perspective Therapeutics Inc

Over the last 18 years, insiders at Perspective Therapeutics Inc have traded over $0 worth of Perspective Therapeutics Inc stock and bought 1,651,741 units worth $855,397 . The most active insiders traders include Lori A Woods, Thomas C Lavoy, and Dwight William Babcock. On average, Perspective Therapeutics Inc executives and independent directors trade stock every 60 days with the average trade being worth of $14,501. The most recent stock trade was executed by Lori A Woods on 13 April 2023, trading 187,500 units of ISR stock currently worth $114,375.

What does Perspective Therapeutics Inc do?

Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium Blu brachytherapy seeds, which are expanding brachytherapy treatment options throughout the body.

Complete history of Mr. Krachon stock trades at Perspective Therapeutics Inc

Perspective Therapeutics Inc executives and stock owners

Perspective Therapeutics Inc executives and other stock owners filed with the SEC include:

• Lori Woods,
  Chief Executive Officer, Director
• Lori A. Holmes-Woods,
  CEO & Director
• Michael Krachon,
  Executive Vice President of Sales and Marketing
• William Cavanagh,
  Chief Research and Development Officer
• Michael L. Krachon,
  Exec. VP of Sales & Marketing
• Jennifer Streeter,
  COO & VP of HR
• William A. Cavanagh III,
  Chief R&D Officer
• Krista Cline,
  Senior Director of Operations, Corporate Secretary
• Philip Vitale,
  Independent Director
• Alan Hoffmann,
  Independent Director
• Jonathan Hunt,
  Chief Financial Officer, Co-Principal Financial Officer
• Mark Austin,
  Controller, Co-Principal Financial and Principal Accounting Officer
• Jennifer Streeter,
  Chief Operating Officer, Vice President of Human Resources
• Michael McCormick,
  Independent Chairman of the Board
• Krista Cline,
  Sr. Director of Operations & Corp. Sec.
• Mark J. Austin CPA,
  VP of Fin., Controller, Co-Principal Financial, Principal Accounting Officer & Sec.
• Jonathan R. Hunt,
  CFO & Co-Principal Financial Officer
• Frank Morich,
  Director
• Brien Ragle,
  Controller
• Dwight William Babcock,
  CEO
• Matthew Branson,
  Principal Fin & Acct Officer
• Robert F Iii Williamson,
  Director
• Thomas C Lavoy,
  Director
• Albert Louis Smith,
  Director
• Roger Girard,
  CEO/President
• Robert R Kauffman,
  Director
• Fredric Swindler,
  Vice President
• David Swanberg,
  EVP Operations & Secretary
• Stephen Boatwright,
  Director